Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

Bibliography

• Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13:806-11
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-20
   PubMed Web of Science ®Google Scholar
• Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008;8:880-7
   PubMed Web of Science ®Google Scholar
• List AF. Vascular endothelial growth factors signaling pathway as an emerging target for hematological malignancies. Oncologist 2001;6(Suppl 5):24-31
   PubMed Web of Science ®Google Scholar
• Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53
   PubMed Web of Science ®Google Scholar
• Kreuter M, Paulussen M, Boeckeler J, et al. Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma. Eur J Cancer 2006;42:1904-11
   PubMed Web of Science ®Google Scholar
• Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004;98:632-6
   PubMed Web of Science ®Google Scholar
• Rosen LS. Clinical experiences with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(Suppl):36-44
   PubMedGoogle Scholar
• Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against Her2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29(Suppl 11):29-37
   PubMed Web of Science ®Google Scholar
• Toi M, Matsumato T, Bando H. Vascular endothelial growth factor: its prognostic, predictive and therapeutic implications. Lancet Oncol 2001;2:667-73
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fenrenbacher L, Novothy W, et al. Bevacizumab in combination with irinotecan/5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer: Results of a randomized Phase III trial. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubins E, et al. Bevacizumab in combination with oxaliplatin based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III trial. J Clin Oncol 2008;26:2013-9
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Co-operative Oncology Group study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel/Carboplatin alone or with Bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel and bevacizumab versus Paclitaxel alone for metastatic breast cancer. N Eng J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Ton NC, Parker GJ, Jackson A, et al. Phase I evaluation of CDP291, a PEGylated di Fab′conjugate that bind VEGFR2. Clin Cancer Res 2007;13:7113-8
   PubMed Web of Science ®Google Scholar
• Camidge DR, Eckhardt SG, Diab S, et al. A Phase I dose-escalation study of weekly IMC-1121B, a fully humanized anti-VEGFR2 IgG1 monoclonal antibody in patients with advanced cancer [abstract 3032]. Proc Am Soc Clin Oncol Meeting 2006;24:128s
   Google Scholar
• Krishnamurthis S, Lorusso PM, Goncalves PH, et al. Phase I study of weekly anti-vascular growth factor-1 monoclonal antibody IMC-18F1 in patients with advanced solid malignancies [abstract 14630]. Proc Am Soc Clin Oncol Meeting 2008;26;637s
   Google Scholar
• Sweeney CJ, Chriorean EG, Mita MM, et al. Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST) [abstract 3523]. Proc Am Soc Clin Oncol Meeting 2008;26:158s
   Google Scholar
• Cherrington JM, Strawn LM, Shawver LK. New paradigns for the treatment of cancer; the role of anti-angiogenic agents, First edition. In: Klein G, Vande Woude GF, editors, Advances in Cancer Research. Academic Press, San Diego, CA; 2000;79. p. 1-38
   Google Scholar
• Khun H, Hammerschmidt S, Wirtz H. Targeting tumor angiogenesis in lung cancer by suppression of vascular endothelial growth factor and its receptor – results from clinical trials and novel experimental approaches. Curr Med Chem 2007;14:3157-65
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 2008;259:378-90
   Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hudson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic reanl cell carcinoma. N Eng J Med 2007;256:115-24
   Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced renal-cell carcinoma. N Eng J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papaopoulous N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50
   PubMed Web of Science ®Google Scholar
• Riely GJ, Miller VA. Vascular endothelial growth factor Trap in non-small cell lung cancer. Clin Cancer Res 2007;13(15 Suppl):4623s-4627s
   PubMed Web of Science ®Google Scholar
• Bryne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-8
   PubMed Web of Science ®Google Scholar
• Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-90
   PubMed Web of Science ®Google Scholar
• Fukusawa M, Korc M. Vascular endothelial growth factor-Trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004;10:3327-32
   PubMed Web of Science ®Google Scholar
• Frischer JS, Huang J, Serur A, et al. Effects of potent VEGF blockade of experimental Wilm's tumor and its persisting vasculature. Int J Oncol 2004;3:549-53
   Google Scholar
• Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75
   PubMed Web of Science ®Google Scholar
• Hu L, Hofmann J, Holash J, et al. Vascular endothelial growth factor Trap combined with paclitaxel stilingly inhibits tumor and ascites, prolongs survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966-71
   PubMed Web of Science ®Google Scholar
• Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007;104:18363-70
   PubMed Web of Science ®Google Scholar
• Wachsberger PR, Burd R, Cadi C, et al. VEGF Trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol 2007;67:1526-37
   PubMed Web of Science ®Google Scholar
• Dupont J, Schwartz LH, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies [abstract 3009]. Proc Am Soc Clin Oncol Meeting 2004;22:197s
   Google Scholar
• Dupont J, Rothernberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors [abstract 3029]. Proc Am Soc Clin Oncol Meeting 2005;23:199s
   Google Scholar
• Massarelli E, Miller VA, Leighl NB, et al. Phase II study of he efficacy and safety of intravenous AVE0005 (VEGF Trap) given every 2 weeks in patients with platinum and erlotinib-resistant adenocarcinoma of lung [abstract 7627]. Proc Am Soc Clin Oncol 2007;25:416s
   Google Scholar
• Tew WO, Colombo N, Ray-Coquard A, et al. VEGF Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: Preliminary results of a randomized Phase II study [abstract 5508]. Proc Am Soc Clin Oncol 2007;25:276s
   Google Scholar
• Tang P, Cohen SJ, Bjarnason GA, et al. Phase II of aflibercept in previously treated patients with metastatic colorectal cancer: A Princess Margaret Hospital Phase II Consortium trial [abstract 4027]. Proc Am Soc Clin Oncol 2008;26:184s
   Google Scholar
• Hobday TJ, Rowland K, Dueck A, et al. N0537: A North Central Cancer Treatment Group (NCCTG) Phase II study of VEGF Trap in patients with metastatic breast cancer previously treated with anthracycline and/or taxanes abstract 164. Proc 2008 Breast Cancer Symposium 2008;167s
   Google Scholar
• Meyer T, Robson T, Amirkhorsravi A, et al. Targeting angiogenesis in cancer: Bevacizumab-induced platelet activation as a possible cause for unexpected arterial thromboembolic events in clinical trials [abstract 1091]. Blood 2006;108:325a
   Google Scholar
• Gerber HO, Wu Y, Yu L, et al. Mice expressing a human form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Am Sci USA 2007;104:3478-83
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radoich M, et al. Asdsociation of vascular growth factopr and vascular growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared to paclitaxel and Bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal caner. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar